U.S. Life Sciences I-Bank Moody Capital Leads Sirona Biochem's US$2.7 Million Placement

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb 22, 2013) - Sirona Biochem Corp. (TSX VENTURE:SBM)(SRBCF)(ZSB.F), (the "Company") announced today a non-brokered private placement of up to 27,000,000 units of the Company at a price of US$0.10 per unit (each a "Unit") for gross proceeds of up to US$2,700,000 (the "Private Placement") led by U.S. Life Sciences Investor Moody Capital Solutions, Inc. (www.moodycapital.com).

"Strong science coupled with attractive unmet markets makes Sirona Biochem an excellent investment for us," said Tim Moody, President and Founder of Moody Capital. "We are impressed with Sirona Biochem''s scientific programs and are confident in the commercial potential of their compounds," added Mr. Moody.

"Moody Capital has provided funding for a number of successful life sciences companies and their support is a testament to the value of our programs and technology platform," said Sirona Biochem Chief Executive Officer, Neil Belenkie. "We are thrilled by Moody Capital''s enthusiasm for our technology and vision," Mr. Belenkie added.

Each Unit will consist of one common share of the Company (a "Share") and one transferable share purchase warrant (a "Warrant"). Each Warrant will entitle the holder to purchase one additional Share of the Company at any time for two years from the closing date of the Private Placement at a price of $0.15 per Share.

The Company is proposing to pay a finder''s fee (the "Finder''s Fees") to finders comprised of a cash fee representing up to 10% of the total proceeds of the Private Placement placed by such finder and warrants (the "Finder''s Warrants") up to 10% of the number of Units the finder sells in the Private Placement. The Finders'' Warrants will be exercisable into one additional Share of the Company at a price of $0.15 per Share for a period of 2 years from the closing date of the Private Placement.

The Company intends to use the proceeds from the Private Placement for research and development, operations, and business development activities. All securities to be issued under the Private Placement will be subject to a hold period in accordance with the Toronto Stock Exchange Venture ("TSXV") and/or other regulatory requirement. Closing of the Private Placement is subject to customary conditions, including TSX Venture Exchange acceptance.

The securities offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or any applicable exemption from the registration requirement of such Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Moody Capital Solutions

Moody Capital provides capital raising, merger and acquisition services and other investment banking services. We service both publicly-listed and privately held small/micro-cap companies. Moody Capital''s senior bankers have extensive experience in community banking, healthcare, life sciences, alternative energy, electronics manufacturing and technology. Our experience includes capital raises directly with the public and using our extensive relationships with leading institutional investors including; private equity firms, venture capital firms, hedge funds and other alternative funding sources. For more information visit www.moodycapital.com.

About Sirona Biochem Corp.

Sirona Biochem is a biotechnology company developing diabetes therapeutics, skin depigmenting and anti-aging agents for cosmetic use, biological ingredients and cancer vaccine antigens. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. Sirona Biochem is the parent company of French-based biotechnology company, TFChem. For more information visit www.sironabiochem.com.

Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem''s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem''s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.